156 related articles for article (PubMed ID: 34844257)
1. The Effect of Intravitreal Bevacizumab Dose on Retinal Vascular Progression in Retinopathy of Prematurity.
Bayramoglu SE; Sayin N
Ophthalmologica; 2022; 245(2):161-172. PubMed ID: 34844257
[TBL] [Abstract][Full Text] [Related]
2. Quantitative Evaluation of Progression of Retinal Vascularization After 60 Weeks Postmenstrual Age in Infants Treated With Bevacizumab.
Bayramoğlu SE; Sayin N
Ophthalmic Surg Lasers Imaging Retina; 2023 Jul; 54(7):417-424. PubMed ID: 37432070
[TBL] [Abstract][Full Text] [Related]
3. Inter-eye comparison of retinal vascular growth rate and angiographic findings following unilateral bevacizumab treatment.
Bayramoglu SE; Sayin N
Eur J Ophthalmol; 2022 May; 32(3):1430-1440. PubMed ID: 34851169
[TBL] [Abstract][Full Text] [Related]
4. Clinical Management of Recurrent Retinopathy of Prematurity after Intravitreal Bevacizumab Monotherapy.
Mintz-Hittner HA; Geloneck MM; Chuang AZ
Ophthalmology; 2016 Sep; 123(9):1845-55. PubMed ID: 27241619
[TBL] [Abstract][Full Text] [Related]
5. Fluorescein Angiography Findings in Treatment-Naive Premature Infants with Retinal Vascular Immaturity and Persistent Avascular Retina.
Bayramoglu SE; Sayın N
Semin Ophthalmol; 2022 Aug; 37(6):740-748. PubMed ID: 35671203
[TBL] [Abstract][Full Text] [Related]
6. Relationship between refractive outcomes and quantitative retinal vascularization and severity of plus disease in eyes treated with intravitreal bevacizumab.
Bayramoglu SE; Sayin N
Indian J Ophthalmol; 2022 Oct; 70(10):3584-3590. PubMed ID: 36190051
[TBL] [Abstract][Full Text] [Related]
7. Factors associated with refractive outcome in children treated with bevacizumab for retinopathy of prematurity: the importance of retinal vascularization.
Bayramoglu SE; Sayin N
Int Ophthalmol; 2022 Oct; 42(10):3199-3210. PubMed ID: 35579771
[TBL] [Abstract][Full Text] [Related]
8. Comparison of fluorescein angiographic findings in type 1 and type 2 retinopathy of prematurity with intravitreal bevacizumab monotherapy and spontaneous regression.
Vural A; Ekinci DY; Onur IU; Hergünsel GO; Yiğit FU
Int Ophthalmol; 2019 Oct; 39(10):2267-2274. PubMed ID: 30604251
[TBL] [Abstract][Full Text] [Related]
9. Computed Analysis of Retinal Vascular Growth After Bevacizumab Treatment of Retinopathy of Prematurity Until Age 3 Years.
Hammer JD; Nguyen H; Palmer J; Furtney S; Agarwal-Sinha S
Clin Ther; 2023 Jan; 45(1):4-16. PubMed ID: 36581528
[TBL] [Abstract][Full Text] [Related]
10. RETINAL VASCULAR DEVELOPMENT WITH 0.312 MG INTRAVITREAL BEVACIZUMAB TO TREAT SEVERE POSTERIOR RETINOPATHY OF PREMATURITY: A Longitudinal Fluorescein Angiographic Study.
Lorenz B; Stieger K; Jäger M; Mais C; Stieger S; Andrassi-Darida M
Retina; 2017 Jan; 37(1):97-111. PubMed ID: 27454223
[TBL] [Abstract][Full Text] [Related]
11. Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity.
Tahija SG; Hersetyati R; Lam GC; Kusaka S; McMenamin PG
Br J Ophthalmol; 2014 Apr; 98(4):507-12. PubMed ID: 24403566
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of retinal vascularization in reactivated retinopathy of prematurity requiring treatment and clinical outcome after reinjection of ranibizumab.
Jang JH
Sci Rep; 2024 Jul; 14(1):15647. PubMed ID: 38977744
[TBL] [Abstract][Full Text] [Related]
13. Long-term retinal vasculature abnormalities following intravitreal bevacizumab for retinopathy of prematurity.
Sternfeld A; Rahmani S; Rossen JL; Zhang DL; Li YD; Quan VL; Huang R; Yoon HH
Graefes Arch Clin Exp Ophthalmol; 2022 Jun; 260(6):1915-1921. PubMed ID: 34851464
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of retinal vascularization in retinopathy of prematurity regressed after intravitreal ranibizumab monotherapy or without treatment based on fluorescein angiography.
Wu L; Li M; Wang L; Yan H; Zhou Z; Fan J; Zhou Y; Gou K; Guo C; Wang Y; Zhang Z
Sci Rep; 2023 Nov; 13(1):19946. PubMed ID: 37968276
[TBL] [Abstract][Full Text] [Related]
15. Fluorescein Angiography in Retinopathy of Prematurity: Comparison of Infants Treated with Bevacizumab to Those with Spontaneous Regression.
Mansukhani SA; Hutchinson AK; Neustein R; Schertzer J; Allen JC; Hubbard GB
Ophthalmol Retina; 2019 May; 3(5):436-443. PubMed ID: 31044736
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Intravitreal Bevacizumab, Intravitreal Ranibizumab and Laser Photocoagulation for Treatment of Type 1 Retinopathy of Prematurity in Turkish Preterm Children.
Kabataş EU; Kurtul BE; Altıaylık Özer P; Kabataş N
Curr Eye Res; 2017 Jul; 42(7):1054-1058. PubMed ID: 28128986
[TBL] [Abstract][Full Text] [Related]
17. Low dose versus conventional dose of intravitreal bevacizumab injection for retinopathy of prematurity: a case series with paired-eye comparison.
Han J; Kim SE; Lee SC; Lee CS
Acta Ophthalmol; 2018 Jun; 96(4):e475-e478. PubMed ID: 27011262
[TBL] [Abstract][Full Text] [Related]
18. Which dose of bevacizumab is more effective for the treatment of aggressive posterior retinopathy of prematurity: lower or higher dose?
Dikci S; Ceylan OM; Demirel S; Yılmaz T
Arq Bras Oftalmol; 2018; 81(1):12-17. PubMed ID: 29538588
[TBL] [Abstract][Full Text] [Related]
19. Conserved regression patterns of retinopathy of prematurity after intravitreal ranibizumab: A class effect.
Ji MH; Moshfeghi DM; Shields RA; Bodnar Z; Ludwig CA; Callaway NF; Orazi L; Amorelli GM; Lepore D
Eur J Ophthalmol; 2021 Jul; 31(4):2135-2140. PubMed ID: 32722932
[TBL] [Abstract][Full Text] [Related]
20. Involution patterns of retinopathy of prematurity after treatment with intravitreal bevacizumab: implications for follow-up.
Isaac M; Tehrani N; Mireskandari K;
Eye (Lond); 2016 Mar; 30(3):333-41. PubMed ID: 26869159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
